Vatera Healthcare Partners leads $67.5m investment in Rib-X Pharmaceuticals

Biopharmaceutical company Rib-X Pharmaceuticals has closed the first tranche of a $67.5m Series 2 preferred stock financing, led by new investor Vatera Healthcare Partners, alongside existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.